Anti-Human CD22 (Epratuzumab Biosimilar)
Catalog #500026
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500026 | 1 mg | $250.00 | ||
| 500026 | 5 mg | $750.00 | ||
| 500026 | 20 mg | $2,000.00 |
Product Details
Epratuzumab is a monoclonal antibody that targets CD22, a cell surface protein primarily found on B-cells. It works by binding to CD22 and interfering with the signaling that is important for the survival and function of B-cells. This mechanism makes it useful in treating autoimmune diseases and B-cell malignancies, including systemic lupus erythematosus (SLE) and non-Hodgkin lymphoma (NHL).
Specifications
| Clone | Epratuzumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CD22 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |